EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Mottet, Nicolas; Bellmunt, Joaquim; Bolla, M.; Briers, Erik; Cumberbatch, Marcus; Santis, Maria De; Fossati, Nicola; Gross, Tobias; Henry, Ann; Joniau, Steven; Lam, Thomas; Mason, Malcolm David; Матвеев, В. Б.; Moldovan, Paul Cezar; Bergh, Roderick C.N. van den; Broeck, Thomas Van den; Poel, Henk G. van der; Kwast, Theodorus H. van der; Rouvière, Olivier; Schoots, Ivo G.; Wiegel, Thomas; Cornford, Philip

doi:10.1016/j.eururo.2016.08.003

Cited by 2,776 publications

(2,541 citation statements)

References 89 publications

Supporting

Mentioning

2,307

Contrasting

Unclassified

Order By: Relevance

“…The purpose of AS is to aim the correct timing for appropriate curative treatment without compromising curative intent, so patient follow-up must be both standardized for a predefined schedule and be individualized for each patient due to different co-morbidities and life-expectancies [3]. One of the largest cohorts with the longest follow-up including 993 patients demonstrated the safety profile of active surveillance as disease-specific survival is 98.1% and 94.3% at 10 and 15 years, respectively [4].…”

Section: Letter To Editormentioning

confidence: 99%

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Şener¹,

Şahin²

2017

Reprod Syst Sex Disord

View full text Add to dashboard Cite

Section: Letter To Editormentioning

confidence: 99%

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Şener¹,

Şahin²

2017

Reprod Syst Sex Disord

View full text Add to dashboard Cite

“…Prostate cancer (PC) still remains the most frequent oncologic disease in the urogenital tract, the second most frequently diagnosed cancer among men and the fifth leading cause of cancer death worldwide [1].…”

Section: Introductionmentioning

confidence: 99%

Partial Nephrectomy as Treatment of an Atypical Metastasis from Prostate Cancer—A Case Report and Review of Literature

Sobrinho¹,

Diniz²,

Martins³

et al. 2018

OJU

View full text Add to dashboard Cite

Background: Prostate cancer is the second most common type of cancer in man and the second in cancer-specific deaths in this population in the world. Most of the causes of death related to prostate cancer are due to its distant metastases, with the most common sites being: skeleton, distant lymph nodes, liver and lung. Renal metastasis is rare, and studies suggest infiltration due to arterial microembolization of the tumor. A key point in this scenario is the clinical suspicion of differential diagnoses, to offer the patient an effective therapy in such a specific case. Aim: To report a case of a patient with prostate cancer undergoing partial nephrectomy whose histopathological report revealed a metastatic lesion of that primary site. Case Presentation: 74 years old man, referred in May 2015 due to high PSA level and lumbago. PSA 323.11 ng/dl, rectal examination cT3a; biopsy was performed and histopathological study reported bilateral prostate adenocarcinoma, Gleason's score 8 (4 + 4). Patient's staging showed multiple secondary implants on skeletal scintigraphy. Tomography revealed solid exophytic lesion in the lower pole of the right kidney (4.7 × 3.6 cm); prostate without cleavage planes with seminal vesicles and pelvic node enlargement. Hormone therapy was initiated, PSA levels dropped to 9.51 ng/dl and total testosterone < 50 ng/dl. Partial nephrectomy was planned, initially by laparoscopy, but converted to laparotomy in December 2015. Procedure lasting 3 hours, minimal blood loss, no perioperative complications, discharged on the 3rd postoperative day. Histopathological report described undifferentiated malignant neoplasm, requiring immunohistochemistry that confirmed prostate adenocarcinoma. Patient remains hormone therapy, with no progression of the disease so far. Conclusion:How to cite this paper: Sobrinho, U

show abstract

“…Medical imaging plays an increasingly important role in the management of prostate cancer and is, amongst others, used for diagnosis and stratification of indolent and clinically significant disease (2), guiding prostate biopsies (3), and targeting localized therapy (4). In Norway, multiparametric MRI, i.e.…”

Section: Introductionmentioning

confidence: 99%

Combined ¹⁸F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Cited by 2,776 publications

References 89 publications

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Partial Nephrectomy as Treatment of an Atypical Metastasis from Prostate Cancer—A Case Report and Review of Literature

Combined ¹⁸F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer

Contact Info

Product

Resources

About

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Cited by 2,776 publications

References 89 publications

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Erectile Dysfunction: The Problem Hiding Behind Prostate Cancer

Partial Nephrectomy as Treatment of an Atypical Metastasis from Prostate Cancer—A Case Report and Review of Literature

Combined 18F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer

Contact Info

Product

Resources

About

Combined ¹⁸F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate Cancer